• linkedin
  • Increase Font
  • Sharebar

    Active surveillance for PCa has ‘hit the prime time’

    Studies show management strategy is increasingly common, safe in favorable-risk disease

    New Orleans—Active surveillance for men with low-risk prostate cancer has made it to prime time.

    That was the message of Stacy Loeb, MD, who moderated a press conference at the AUA annual meeting, where four studies documented the increasing popularity and safety of active surveillance in managing low-risk disease. The panel included experts from Johns Hopkins University in Baltimore, the University of California, Los Angeles, and New York University, New York, where Dr. Loeb is assistant professor of urology. 

    For years, Dr. Loeb said prostate cancer has been over-diagnosed and over-treated, but recent data suggest that active surveillance is helping to address the problem.

    “Active surveillance use is really expanding rapidly. It has finally hit the prime time and is not experimental treatment anymore. Now, this is really what we should be promoting for our patients,” Dr. Loeb told Urology Times.

    NEXT: A safe management strategy 


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available